Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gynecology

PUBLISHER: Grand View Research | PRODUCT CODE: 1552540

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1552540

U.S. Women's Health Market Size, Share & Trends Analysis Report By Application (Contraceptives, Endometriosis & Uterine Fibroids), By Age (50 Years & Above, Others), By Drug (Prolia, XGEVA), And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 130 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

U.S. Women's Health Market Growth & Trends:

The U.S. women's health market size is expected to reach USD 29.68 billion by 2030, expanding at a CAGR of 4.04% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.

The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades. This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives. For instance, in 2019, the U.S. government provided USD 608 million in funding to UNFPA for family planning & reproductive health development.

Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women's health are being undertaken in the country, which involve advocating for policy changes, promoting girls' education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.

Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women's Health networks to address women's health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women's health.

U.S. Women's Health Market Report Highlights:

  • Based on drug, the Prolia drug segment held the largest revenue share in 2023 and is anticipated to grow at the fastest CAGR over the forecast period owing to the wide adoption of the drug with very less side effects
  • Based on application, the contraceptives segment is expected to showcase the fastest CAGR over the forecast period, owing to an increase in awareness about family planning
  • Based on age, the others age segment dominated the U.S. women's health industry in 2023, due to the rising concerns of fertility, such as endometriosis, hormonal infertility, and PCOS in this age group
  • Based on distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the high stock and availability of women's health therapeutics in the hospital pharmacies
  • Key market players are constantly focusing on product launches and geographical expansion to maintain their presence
Show more
Product Code: GVR-4-68040-106-9

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Age
    • 1.2.3. Drug
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database.
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Age outlook
    • 2.2.3. Drug outlook.
  • 2.3. Competitive Insights

Chapter 3. U.S. Women's Health Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of target diseases
      • 3.2.1.2. Increasing initiatives by government and various organizations
      • 3.2.1.3. Rising publicly funded family planning services
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of major drugs
      • 3.2.2.2. Lawsuits related to products.
      • 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices.
  • 3.3. U.S. Women's Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. U.S. Women's Health Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Women's Health Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Hormonal infertility
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Contraceptives
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Postmenopausal osteoporosis
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Endometriosis & uterine fibroids
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Menopause
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Polycystic ovary syndrome (PCOS)
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Women's Health Market: Drug Estimates & Trend Analysis

  • 5.1. Drug Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Women's Health Market by Drug Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. ACTONEL
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. YAZ, Yasmin, Yasminelle
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. FORTEO
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Minastrin 24 Fe
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Mirena
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. NuvaRing
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. ORTHO TRI-CY LO
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Premarin
      • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.9. Prolia
      • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.10. Reclast/Aclasta
      • 5.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.11. XGEVA
      • 5.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.12. Zometa
      • 5.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.13. Others
      • 5.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Women's Health Market: Age Estimates & Trend Analysis

  • 6.1. Age Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Women's Health Market by Age Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. 50 years and above
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Postmenopausal osteoporosis
        • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Endometriosis & uterine fibroids
        • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.4. Menopause
        • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.5. Others
        • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Others
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. AbbVie, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Bayer AG
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Merck & Co., Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Pfizer, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Teva Pharmaceutical Industries Ltd.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Agile Therapeutics
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Amgen, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Apothecus Pharmaceutical Corp.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Eli Lilly and Company
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Ferring B.V.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-106-9

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Women's Health Market, by application, 2018 - 2030 (USD Million)
  • Table 3 U.S. Women's Health Market, by drug, 2018 - 2030 (USD Million)
  • Table 4 U.S. Women's Health Market, by age, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Women's Health Market: market outlook
  • Fig. 10 Women's health competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Women's Health Market driver impact
  • Fig. 16 U.S. Women's Health Market restraint impact
  • Fig. 17 U.S. Women's Health Market strategic initiatives analysis
  • Fig. 18 U.S. Women's Health Market: Application movement analysis
  • Fig. 19 U.S. Women's Health Market: Application outlook and key takeaways
  • Fig. 20 Hormonal infertility market estimates and forecast, 2018 - 2030
  • Fig. 21 Contraceptives estimates and forecast, 2018 - 2030
  • Fig. 22 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
  • Fig. 23 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
  • Fig. 24 Menopause market estimates and forecast, 2018 - 2030
  • Fig. 25 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
  • Fig. 26 U.S. Women's Health Market: Drug movement analysis
  • Fig. 27 U.S. Women's Health Market: Drug outlook and key takeaways
  • Fig. 28 ACTONEL market estimates and forecast, 2018 - 2030
  • Fig. 29 YAZ, Yasmin, Yasminelle estimates and forecast, 2018 - 2030
  • Fig. 30 FORTEO market estimates and forecast, 2018 - 2030
  • Fig. 31 Minastrin 24 Fe estimates and forecast, 2018 - 2030
  • Fig. 32 Mirena market estimates and forecast, 2018 - 2030
  • Fig. 33 NuvaRing estimates and forecast, 2018 - 2030
  • Fig. 34 ORTHO TRI-CY LO market estimates and forecast, 2018 - 2030
  • Fig. 35 Premarin estimates and forecast, 2018 - 2030
  • Fig. 36 Prolia market estimates and forecast, 2018 - 2030
  • Fig. 37 Reclast/Aclasta estimates and forecast, 2018 - 2030
  • Fig. 38 XGEVA market estimates and forecast, 2018 - 2030
  • Fig. 39 Zometa estimates and forecast, 2018 - 2030
  • Fig. 40 Others estimates and forecast, 2018 - 2030
  • Fig. 41 U.S. Women's Health Market: Age movement Analysis
  • Fig. 42 U.S. Women's Health Market: Age outlook and key takeaways
  • Fig. 43 50 years and above market estimates and forecasts, 2018 - 2030
  • Fig. 44 Postmenopausal osteoporosis market estimates and forecasts,2018 - 2030
  • Fig. 45 Endometriosis & uterine fibroids market estimates and forecasts,2018 - 2030
  • Fig. 46 Menopause market estimates and forecasts,2018 - 2030
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030
  • Fig. 49 Market share of key market players - U.S. Women's Health Market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!